GlassScriptPhysician profile
Ethan J Wasserman
NPI 1811104292
$7,547.87
in general payments reported to CMS, 2019-2025
59 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $881 · 2021: $549 · 2022: $881 · 2023: $1,137 · 2024: $1,507 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436 · Education: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,435.51 |
| Education | $771.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $630.14 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $614.56 | 2019-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $576.66 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $485.83 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $470.50 | 2019-2025 | |
| Janssen Biotech, INC. | $431.81 | 2019-2024 | Erleada, Akeega, Balversa |
| Pfizer INC. | $384.39 | 2019-2025 | |
| Eisai INC. | $363.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $336.89 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $326.24 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $312.61 | 2019-2025 | |
| Seagen INC. | $306.58 | 2019-2023 | Padcev, Adcetris |
| Glaxosmithkline, LLC. | $207.30 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $174.70 | 2022-2025 | Padcev, Xtandi, Xospata |
| Pharmacyclics LLC, An Abbvie Company | $158.20 | 2019-2020 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $141.63 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.60 | 2023-2025 | Libtayo |
| Array Biopharma INC | $124.98 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $120.48 | 2020-2025 | Yescarta |
| Lilly USA, LLC | $114.95 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Taiho Oncology, INC. | $94.07 | 2024-2025 | |
| Amgen INC. | $82.72 | 2019-2022 | |
| Blueprint Medicines Corporation | $72.72 | 2022-2025 | Ayvakit |
| Emd Serono, INC. | $61.87 | 2019-2025 | |
| Abbvie INC. | $52.59 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $44.50 | 2024-2025 | Monoferric, Cosela |
| Celgene Corporation | $43.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.35 | 2019-2023 | Alunbrig |
| Ipsen Biopharmaceuticals, INC | $40.11 | 2024 | Somatuline Depot, Onivyde |
| Servier Pharmaceuticals LLC | $37.15 | 2025 | |
| Geron Corporation | $33.68 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $32.45 | 2025 | Brukinsa |
| Exelixis INC. | $32.14 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $27.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.39 | 2021 | |
| Karyopharm Therapeutics INC. | $23.46 | 2021 | |
| Novocure INC. | $22.91 | 2025 | Optune Lua (Novottf-200t) |
| Adaptive Biotechnologies Corporation | $21.68 | 2023 | Clonoseq |
| Beigene USA, INC. | $19.99 | 2025 | Tevimbra |
| Rigel Pharmaceuticals, INC. | $19.87 | 2024 | Rezlidhia, Tavalisse |
| Secura Bio, INC. | $19.01 | 2023 | Copiktra |
| Janssen Pharmaceuticals, INC | $18.70 | 2024 | Xarelto |
| Mirati Therapeutics, INC. | $18.33 | 2024 | Krazati |
| Tempus Ai, INC | $17.75 | 2024 | Xt Cdx |
| Aadi Bioscience, INC. | $17.70 | 2024 | Fyarro |
| Azurity Pharmaceuticals, INC. | $16.81 | 2025 | Vivimusta |
| Morphosys, US INC. | $15.53 | 2022 | |
| Medtronic, INC. | $14.97 | 2025 | Synchromedii |
| Clovis Oncology, INC. | $14.93 | 2019 | |
| Tersera Therapeutics LLC | $14.91 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $14.69 | 2019 | |
| Acrotech Biopharma INC. | $14.49 | 2024 | Ryzneuta |
| Stemline Therapeutics INC. | $14.40 | 2024 | Orserdu |
| Dova Pharmaceuticals | $13.75 | 2019 | |
| Sumitomo Pharma America, INC. | $13.65 | 2023 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $13.56 | 2025 | Givlaari |
| Genzyme Corporation | $13.54 | 2019 | |
| Heron Therapeutics, INC. | $7.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.